IP Library Patent Application 15086479
Patent Application
App. No. 15/086,479

CEFTOLOZANE ANTIBIOTIC COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/086,479
Abstract

This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.

Claims (24)

1 - 26 . (canceled)

27 . A solid pharmaceutical composition comprising ceftolozane or a pharmaceutically acceptable salt thereof and tazobactam sodium, said composition comprising less than 0.1% by weight of a compound of formula (III)

when stored for 1 month at a temperature of 25° C. and at a relative humidity of 60%, wherein the ceftolozane or pharmaceutically acceptable salt thereof and tazobactam sodium provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight.

28 . The composition of claim 27 , wherein the pharmaceutically acceptable salt of ceftolozane is ceftolozane sulfate.

29 . The composition of claim 48 , which is provided in a unit dosage form.

30 . The composition of claim 48 , which contains less than 0.05% by weight of the compound of formula (III) when stored for 1 month at a temperature of 25° C. and at a relative humidity of 60%.

31 . The composition of claim 48 , which contains less than 0.03% by weight of the compound of formula (III) when stored for 1 month at a temperature of 25° C. and at a relative humidity of 60%.

32 . The composition of claim 48 , wherein the compound of formula (III) is not present when stored for 1 month at a temperature of 25° C. and at a relative humidity of 60%.

33 . The composition of claim 48 , wherein the amount of ceftolozane active is 1,000 mg and the amount of tazobactam active is 500 mg.

34 . The composition of claim 48 , wherein the amount of ceftolozane active is 2,000 mg and the amount of tazobactam active is 1,000 mg.

35 . The pharmaceutical composition of claim 48 , comprising 1147 mg ceftolozane sulfate and 537 mg tazobactam sodium.

36 . An injectable solution comprising a pharmaceutical composition of claim 48 dissolved in a pharmaceutically acceptable vehicle.

37 . The injectable solution of claim 56 , wherein the pharmaceutically acceptable vehicle is selected from water, 0.9% sodium chloride and 5% Dextrose.

38 . A pharmaceutical composition comprising ceftolozane or a pharmaceutically acceptable salt thereof and tazobactam sodium, said composition comprising less than 0.1% of a material having a mass spectra depicted in FIG. 14 , wherein the ceftolozane or pharmaceutically acceptable salt thereof and tazobactam sodium provide ceftolozane active and tazobactam active in a ratio of 2:1 by weight.

39 . The composition of claim 58 , wherein the pharmaceutically acceptable salt of ceftolozane is ceftolozane sulfate.

40 . The composition of claim 59 , which is provided in a unit dosage form.

41 . The composition of claim 59 , which contains less than 0.05% by weight of the material with the mass spectra depicted in FIG. 14 when stored for 1 month at a temperature of 25° C. and at a relative humidity of 60%.

42 . The composition of claim 59 , which contains less than 0.03% by weight of the material with the mass spectra depicted in FIG. 14 when stored for 1 month at a temperature of 25° C. and at a relative humidity of 60%.

43 . The composition of claim 48 , wherein the material with the mass spectra depicted in FIG. 14 is not present when stored for 1 month at a temperature of 25° C. and at a relative humidity of 60%.

44 . The composition of claim 59 , wherein the amount of ceftolozane active is 1,000 mg and the amount of tazobactam active is 500 mg.

45 . The composition of claim 59 , wherein the amount of ceftolozane active is 2,000 mg and the amount of tazobactam active is 1,000 mg.

46 . The pharmaceutical composition of claim 59 , comprising 1147 mg ceftolozane sulfate and 537 mg tazobactam sodium.

47 . An injectable solution comprising a pharmaceutical composition of claim 59 dissolved in a pharmaceutically acceptable vehicle.

48 . The injectable solution of claim 67 , wherein the pharmaceutically acceptable vehicle is selected from water, 0.9% sodium chloride and 5% Dextrose.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2016
From: TERRACCIANO, JOSEPH
To: CUBIST PHARMACEUTICALS, INC.
Reel/Frame 039779/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2016
From: DAMOUR, NICOLE MILLER
To: CUBIST PHARMACEUTICALS, INC.
Reel/Frame 039779/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2016
From: JIANG, CHUN
To: CALIXA THERAPEUTICS, INC
Reel/Frame 039779/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2016
From: FOGLIATO, GIOVANNI; DONADELLI, GIUSEPPE ALESSANDRO; RESEMINI, DARIO
To: ACS DOBFAR S.P.A.
Reel/Frame 039780/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2016
From: ACS DOBFAR S.P.A.
To: CUBIST PHARMACEUTICALS LLC
Reel/Frame 039780/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2016
From: CUBIST PHARMACEUTICALS, INC.
To: CALIXA THERAPEUTICS, INC
Reel/Frame 039780/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2016
From: CALIXA THERAPEUTICS, INC
To: MERCK SHARP & DOHME CORP.
Reel/Frame 039780/0622 →